TrianglePembrolizumab (NCT05726370)
Pembrolizumab trial for Head and Neck Squamous Cell Carcinoma (NCT05726370). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with operable, locally recurrent head-and-neck squamous cancer, or a new cancer in a previously irradiated field, at least six months after treatment. Prior checkpoint immunotherapy excludes participation.
The idea: pembrolizumab releases a PD1 immune brake. Two three-week cycles combine it with docetaxel and either cisplatin or carboplatin before surgery. Pembrolizumab continues for up to fifteen cycles afterward. Researchers examine tissue for response. Pretreatment biopsy is required; exceptions need sponsor discussion.
This phase 2 study plans 28 patients. Kartik Sehgal leads at Dana-Farber, Boston, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.